Portland Global Advisors LLC Raises Holdings in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Portland Global Advisors LLC increased its position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 3.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 268,988 shares of the company’s stock after buying an additional 9,373 shares during the period. Portland Global Advisors LLC owned about 3.86% of Global X Genomics & Biotechnology ETF worth $2,612,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in Global X Genomics & Biotechnology ETF during the fourth quarter valued at approximately $2,974,000. Flow Traders U.S. LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the third quarter worth $936,000. Rockefeller Capital Management L.P. acquired a new position in shares of Global X Genomics & Biotechnology ETF in the 3rd quarter valued at about $205,000. Sei Investments Co. acquired a new position in shares of Global X Genomics & Biotechnology ETF in the 4th quarter valued at $114,000. Finally, Corrado Advisors LLC boosted its position in Global X Genomics & Biotechnology ETF by 17.3% during the fourth quarter. Corrado Advisors LLC now owns 75,323 shares of the company’s stock worth $731,000 after purchasing an additional 11,099 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors.

Global X Genomics & Biotechnology ETF Stock Performance

Shares of NASDAQ GNOM opened at $8.35 on Friday. The firm has a market cap of $58.20 million, a PE ratio of -3.57 and a beta of 1.03. The firm has a fifty day moving average of $9.44 and a 200 day moving average of $10.14. Global X Genomics & Biotechnology ETF has a one year low of $8.31 and a one year high of $11.88.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.